权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Manufacturing USA: Biomanufacturing of Cell Microparticles from Stem Cells As Novel Thrombotic Therapeutic Agents

美国制造：利用干细胞生物制造细胞微粒作为新型血栓治疗剂

基本信息

批准号：
1804741
负责人：
Eleftherios Papoutsakis
金额：
$ 50万
依托单位：
University of Delaware
依托单位国家：
美国
项目类别：
Standard Grant
财政年份：
2018
资助国家：
美国
起止时间：
2018-08-01 至 2023-07-31
项目状态：
已结题

来源：
https://www.nsf.gov/awardsearch/showAward?AWD_ID=1804741&HistoricalAwards=false
关键词：
Manufacturing USA Biomanufacturing Cell Microparticles

项目摘要

Cell and gene therapies can be used to treat a large array of diseases. Therapy is based on using whole cells or viruses to deliver genes or proteins to the patient. Membrane sacs, known as extracellular vesicles (EVs), are a promising new delivery system. They can target specific types of cells for delivery of their cargo, and can carry proteins, fats and ribonucleic acids. This project will develop EV technology based on specialized cells in the bone marrow that generate platelets. Development of this technology could lead to new strategies for solving long-standing problems in Transfusion Medicine by providing a stable and abundant source of platelets. High school and college students from underrepresented groups will engage in research experiences to stimulate their interest in engineering and biomanufacturing careers. The goal of this project is to develop foundational science and engineering for preparing functional extracellular vesicles (EVs) to enable novel cell and gene therapies. EVs are submicron membrane vesicles that carry RNAs, proteins and lipids from their parent cells. Cells use EVs to communicate with other cells, delivering signals through their content, and targeting a rather narrow range of cell types through receptor-recognition mechanisms based on surface proteins. It is now widely accepted that extracellular vesicles are excellent candidates for enabling safe and potent cell and gene therapies. This project will focus on megakaryocytic microparticles (MPs; a type of extracellular vesicles), which target and deliver cargo to hematopoietic stem & progenitor cells (HSPCs). The most important feature of these MPs is that they specifically target HSPCs and program them to generate more megakaryocytes, the precursors of platelets. This project will develop characterization methods and assays for these MPs so that they can be used to develop robust protocols for generating large MP quantities. Finally, the project will also assess the biological efficacy of these MPs as thrombotic agents using a simple murine model.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

细胞和基因疗法可用于治疗多种疾病。治疗的基础是使用整个细胞或病毒将基因或蛋白质传递给病人。膜囊，被称为细胞外囊泡（EVs），是一种很有前途的新型递送系统。它们可以针对特定类型的细胞来运送它们的货物，并且可以携带蛋白质、脂肪和核糖核酸。该项目将开发基于骨髓中产生血小板的特殊细胞的EV技术。这项技术的发展可以通过提供稳定和丰富的血小板来源，为解决输血医学中长期存在的问题提供新的策略。来自代表性不足群体的高中生和大学生将参与研究经验，以激发他们对工程和生物制造职业的兴趣。该项目的目标是为制备功能性细胞外囊泡（EVs）发展基础科学和工程，以实现新的细胞和基因治疗。电动汽车是亚微米的膜囊泡，携带来自其母细胞的rna、蛋白质和脂质。细胞利用ev与其他细胞进行通信，通过其内容传递信号，并通过基于表面蛋白的受体识别机制靶向相当窄范围的细胞类型。现在人们普遍认为，细胞外囊泡是实现安全和有效的细胞和基因治疗的绝佳候选者。该项目将重点研究巨核细胞微颗粒（MPs，一种细胞外囊泡），其靶向并向造血干细胞和祖细胞（HSPCs）运送货物。这些MPs最重要的特点是它们专门针对HSPCs，并对其进行编程，使其产生更多的巨核细胞，即血小板的前体。该项目将开发这些MPs的表征方法和分析方法，以便它们可以用于开发生成大量MPs的稳健协议。最后，该项目还将使用简单的小鼠模型评估这些MPs作为血栓形成剂的生物学功效。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。